Advertisement
Screener

Protagenic Therapeutics, Inc.\new (PTIX) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price

Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price

Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.48 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-07.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2022-04-07

  • Protagenic Therapeutics, Inc.\new share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.00.
  • Protagenic Therapeutics, Inc.\new share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $1.48.
Period endShare-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month
2021-12-31$1.48
10-K · filed 2022-04-07
2021-09-30$1.48
10-Q · filed 2021-11-15
2021-06-30$1.48
10-Q · filed 2021-08-16
2021-03-31$1.00
10-Q · filed 2021-05-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
CDT Equity Inc. (CDT)United States$0.000B-0.01
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Aditxt, Inc. (ADTX)United States$0.000B
Rafael Holdings, Inc. (RFL)United States$0.000B-0.00